Introducing home treatment with bortezomib (Velcade®)
The COVID-19 pandemic brought challenges to the delivery of care for haematology patients on an unprecedented level. Teams faced an urgent need to restructure ‘routine’ services to allow myeloma treatments to carry on as much as possible, while also reducing the risk to this particularly vulnerable group of patients.
Starting up video consultations and digital clinics
During our CSEP visits at Queen Hospital, Burton, we were impressed by their use of video consultations and how quickly they got them up and running during the pandemic. We caught up with Consultant Haematologist, Dr Hume Ahmad to find out how he is using video consultations and if he has tips for anyone wanting…
A close partnership between haematology and renal teams achieves best possible outcomes
Approximately 20% of newly diagnosed myeloma patients have significant renal impairment at the time of their diagnosis, and about 10% of these immediately require dialysis. The renal complications of myeloma are amongst the most important in terms of their potential to affect patients’ quality of life. This is particularly true for patients who need dialysis…